Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

32.5% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 3.6% of Mallinckrodt shares are owned by insiders. Strong ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a ...

Galapagos NV (NASDAQ:GLPG) is under modest pressure premarket, down 6% on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:VRTX) triple... BySeeking Alpha ...

At close: January 23 at 4:00:02 PM EST ...